Skip to content
Screener

QuidelOrtho Corporation QDEL North America — R&D

Other segment segments

China
$600K-25.0%
Latin America
$600K+20.0%
JPAC
$300K-25.0%
EMEA
$100K-85.7%

Similar metrics at other companies

Aebi Schmidt Holding logo
AEBINorth America — R&D
$1.63M+172%
Helmerich & Payne logo
HPNorth America Solutions — R&D
$6.02M-21.0%
Brady Corporation logo
BRCAmericas & Asia — R&D
$16.95M+27.3%
MSA
MSAAmericas segment — R&D
$9.64M+2.9%
Veradermics logo
MANER&D
$20.93M+82.8%
Polaryx Therapeutics, Inc. logo
PLYXR&D
$679K-85.6%

Other financials

Income statement

See full
Revenue$630.9M+2.8%
Gross profit$272.9M-0.7%
Operating income-$21.8M+87.9%
Net income-$92.9M+63.6%
EPS (diluted)-$1.36+63.9%

Balance sheet

See full
Cash & equivalents$123.4M-18.7%
Total debt$3.4B+3.0%
Total equity$1.8B-36.4%
Total assets$5.7B-10.4%

Cash flow

See full
Operating cash flow-$110.6M
CapEx$25.5M-32.0%
Free cash flow-$136.1M-61.4%

Valuation

See full
Market cap$837.73M-47.8%
Enterprise value$4.15B-13.4%
P/S0.3×-0.3×

Profitability

See full
Gross margin44.6%-2.7pp
Operating margin-30.8%-49.9pp
Net margin-39.2%-168pp
FCF margin13.8%

Returns & leverage

See full
Return on equity-45.9%-94.9pp
Debt / equity1.9×+0.7×
Current ratio1.4×+0.3×

Where this comes from

Reported directly by QuidelOrtho Corporation in its filing.

Tagged under the XBRL concept qdel:SegmentInformationResearchAndDevelopmentExpense.

The source filing: QuidelOrtho Corporation’s 10-Q, filed August 7, 2026.

Filed
Aug 6, 2026, 8:00 PM EDT
Fiscal quarter
Q2 FY2026
Calendar quarter
Q3 2026
Accession
0001906324-26-000033
(In millions)North AmericaEMEAChinaJPACLatin AmericaTotal
Less (1):
Cost of sales, excluding amortization of intangibles116.744.328.843.338.3271.4
Selling, marketing and administrative40.723.99.512.313.299.6
Research and development0.40.10.60.30.62.0
Other expense, net0.8(1.4)0.1(1.6)(2.1)
Total segment Adjusted EBITDA$169.6$22.1$30.3$18.3$19.7260.0
Reconciliation of segment Adjusted EBITDA
Corporate (2)(130.7)

Item 1. Financial Statements (unaudited)

FAQ

What is QuidelOrtho Corporation's north america — R&D?
QuidelOrtho Corporation (QDEL) reported north america — R&D of $400K in Q2 2026.
How has QuidelOrtho Corporation's north america — R&D changed year-over-year?
QuidelOrtho Corporation's north america — R&D decreased by 0.0% year-over-year, from $400K to $400K.
What is the long-term trend for QuidelOrtho Corporation's north america — R&D?
Over 3 years (2022 to 2025), QuidelOrtho Corporation's north america — R&D has grown at a 17.0% compound annual growth rate (CAGR), from $1M to $1.6M.
What does north america — R&D mean?
Represents the expenditures dedicated to the innovation, development, and improvement of diagnostic testing technologies within the North American segment. This investment is critical for maintaining long-term competitiveness and expanding the product portfolio.

Ask your AI about QuidelOrtho Corporation's north america — r&d.

Connect your AI assistant and compare segments, right in your chat.

Connect your AI
Harbor at dusk
Claude